Program
HRS-6768
A development code.
In Jiangsu HengRui Medicine's pipeline, FAP-α
. Its studies are led by Jiangsu HengRui Medicine.
Furthest: phase 2, since Apr 7, 20251 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 11 open or running | phase 2since Apr 7, 2025 | Apr 7, 2025 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-6768
, phase 1, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 7, 2025First study: phase 2 study in Advanced Solid TumorsFirst studyNCT06925581 · 84 planned · China
TargetBeta
“FAP-α”the company's pipeline, read by Claude · source
Other programs on FAP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lutetium-177 | Novartis | phase 3 | 24 |
| Gallium-68 | Philogen | phase 3 | 17 |
| Fluorine F 18 FAPI-74rule | sofie | phase 3 | 3 |
| Fluorine F 18 FPyQCPrule | Bracco | phase 2 | 1 |
| Anti-FAP Antibody-drug Conjugate OMTX705rule | oncomatryx-biopharma-s-l | phase 1 | 2 |
| Gallium Ga 68 NNS309 | Novartis | phase 1 | 2 |
| Actinium Ac 225 RTX-2358rule | ratio-therapeutics-inc | phase 1 | 1 |
| Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713rule | Eli Lilly | phase 1 | 1 |
| Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050rule | Immunome | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06925581Advanced Solid Tumors · China | 2 | Recruiting | Apr 2026 | 84 |
How it is read
Names in the registry
- “HRS-6768”, 1 entry
Codes read as this program: HRS6768.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.